COVID-19 Clinical Trial
Official title:
A Clinical Trial to Evaluate the Safety and Efficacy of Mycobacterium W in Critically Ill Patients Suffering From COVID 19 Infection
Verified date | January 2021 |
Source | Cadila Pharnmaceuticals |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The trial is randomized, blinded, two arms, active comparator controlled, clinical trial to evaluate the safety and efficacy of Mycobacterium w in combination with standard care as per hospital practice versus standard care alone in critically ill adult patients suffering from COVID-19 infection.
Status | Completed |
Enrollment | 40 |
Est. completion date | August 21, 2020 |
Est. primary completion date | August 10, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Critically ill patients infected with COVID-19 (clinical/confirmed) - Patient aged 18 years or more of either gender - Illness of any duration with respiratory rate =25 breaths/minute, and at least one of the following: - Radiographic infiltrates by imaging (chest x-ray, CT scan, etc.), or or - SpO2 =94% on room air, or - Requiring mechanical ventilation and/or supplemental oxygen - Female patients of childbearing potential must have a negative pregnancy test within 14 days prior to first dose of study medication. - Subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedure. Exclusion Criteria: - Pregnant or nursing female. - Patients with history of allergy, hypersensitivity, or any serious reaction to study medication - Patients with a concomitant medical condition, whose participation, in the opinion of the investigator, may create an unacceptable additional risk. - Patient previously enrolled into this study. - Patient participating or having participated in a clinical trial with another investigational drug within the last 28 days except for investigational drugs against cancer, leukaemia or HIV. - Patients with a life expectancy judged to be less than five days - ALT/AST > 5 times the upper limit of normal - Stage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR < 30) - Patients not likely to complete the trial as per judgment of the investigator. |
Country | Name | City | State |
---|---|---|---|
India | All India Institute of Medical Sciences, Bhopal | Bhopal | Madhya Pradesh |
India | Postgraduate Institute of Medical Education and Research | Chandigarh | |
India | All lndia Institute of Medical Science, Delhi | Delhi | |
India | All India Institute of Medical Science, Raipur | Raipur | Chhattisgarh |
Lead Sponsor | Collaborator |
---|---|
Cadila Pharnmaceuticals | Council of Scientific and Industrial Research, India |
India,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 7-category ordinal scale that ranges from 1 (not hospitalized with resumption of normal activities) to 7 (death) | To study the effect of Mw on recovery of organ function as assessed by Ordinal scale | Change in Ordinal scale from baseline to day 3, day 7, day 14, day 21 and day 28 and day of transfer from ICU, if discharged earlier than 28 days post-randomization. | |
Primary | Sequential Organ Failure Assessment (SOFA) scores | To study the effect of Mw on recovery of organ function as assessed by Sequential Organ Failure Assessment (SOFA) which is based on six different scores, one for each of the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems each scored from 0 to 4 with an increasing score reflecting worsening organ dysfunction | Change in SOFA score from baseline to day 3, day 7, day 14, day 21 and day 28 and day of transfer from ICU, if discharged earlier than 28 days post-randomization. | |
Secondary | Incidence of AE / SAE or event of clinical significance | Any AE / SAE or event of clinical significance observed during the study. | Till day 28 | |
Secondary | SARS-CoV-2 detectable in nasal or oropharyngeal (OP) sample | Percent of subjects with SARS-CoV-2 detectable in nasal or oropharyngeal (OP) sample. | At days 3, 7, 14, 21, and 28 | |
Secondary | ICU length of stay | ICU length of stay | Till day 28 | |
Secondary | Duration of mechanical ventilation | Duration of mechanical ventilation | Till day 28 | |
Secondary | Duration of hospitalization | Duration of hospitalization | Till day 28 | |
Secondary | Clinical improvement | Percentage of subjects having clinical improvement defined as two-point improvement on a seven category ordinal scale. | From baseline to day 14 & Day 28 | |
Secondary | Time (in days) from treatment initiation to death | Time (in days) from treatment initiation to death. | Till day 28 | |
Secondary | All-cause mortality | All-cause mortality | Till day 28 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|